About
Endeavor BioMedicines is a clinical-stage biotechnology company developing therapeutic candidates targeting the Hedgehog signaling pathway, with its lead drug taladegib (ENV-101) in clinical trials for fibrotic lung diseases such as idiopathic pulmonary fibrosis.
Explore Endeavor BioMedicines's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.